Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies

Pancreatic cancer remains largely an incurable disease necessitating the development of novel therapeutic approaches. Adoptive immunotherapy using chimeric antigen receptor (CAR)-transduced T cells represents an alternative treatment with curative potential. We present an overview of the engineering...

Descripción completa

Detalles Bibliográficos
Autores principales: Abate-Daga, Daniel, Rosenberg, Steven A, Morgan, Richard A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108460/
https://www.ncbi.nlm.nih.gov/pubmed/25083334
http://dx.doi.org/10.4161/onci.29194
Descripción
Sumario:Pancreatic cancer remains largely an incurable disease necessitating the development of novel therapeutic approaches. Adoptive immunotherapy using chimeric antigen receptor (CAR)-transduced T cells represents an alternative treatment with curative potential. We present an overview of the engineering of novel CARs targeting prostate stem cell antigen (PSCA), implications for the development of immunotherapies, and potential strategies to circumvent on-target/off-tumor toxicities.

Ejemplares similares